Fig. 2: Effects of CREB-HDO on beneficial effects of (R)-ketamine on depression-like behaviors, and expression of p-CREB, CREB, BDNF, MeCP2, and CD11b in the mPFC.
From: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
A Schematic illustration of the construction of ASO, cRAN, and HDO. B Graphical illustration of intracerebroventricular (i.c.v.) injection site and the distribution of CY5-CREB-HDO in the brain. C The schedule of CSDS, treatment, behavioral tests, and sample collection. CSDS was performed from day 1 to day 10. On day 11, social interaction test (SIT) was performed to select CSDS susceptible mice. CREB-HDO or vehicle was injected i.c.v. to mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg). Subsequently, behavioral tests such as locomotion tests (LMT), forced swimming test (FST), and sucrose preference test (SPT) were performed. D LMT. E FST. F SPT. The data are the mean ± SEM (n = 7 or 8). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). G The expression of p-CREB, CREB, BDNF, and MeCP2 in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). H The immunofluorescence analysis for p-CREB and CD11b in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01; ***P < 0.001 (one-way ANOVA). Scale bar = 50 μm.
